<DOC>
	<DOCNO>NCT03044314</DOCNO>
	<brief_summary>This study compare clinical efficacy inhale iloprost invasive , selective vasodilator cardiac catheterization laboratory patient pulmonary hypertension gold standard inhale nitric oxide . It also examine whether echocardiographic estimate response inhale iloprost predict responsiveness invasive vasodilator test patient pulmonary hypertension .</brief_summary>
	<brief_title>Outpatient Vasodilator Assessment Using Iloprost Pulmonary Hypertension</brief_title>
	<detailed_description>Iloprost first inhale prostacyclin analogue FDA-approved treatment pulmonary arterial hypertension . Iloprost aerosol show significantly improve pulmonary hemodynamics patient idiopathic pulmonary hypertension ( PH ) , effect great nitric oxide sildenafil . It also show effective nitric oxide reduce pulmonary arterial pressure ( PAP ) prostacyclin infusion use cardiac catheterization laboratory . Because administration inhalational mean , iloprost advantage selective action pulmonary vasculature avoidance systemic side effect plague many treatment PH . The investigator intend compare efficacy inhale iloprost reduce pulmonary artery pressure gold standard nitric oxide patient pulmonary hypertension . Without establish noninvasive algorithm identify beneficial hemodynamic response vasodilator , patient pulmonary hypertension ( PH ) routinely subject expensive invasive testing . Echocardiography routinely use facilitate diagnosis PH echocardiographically-derived estimate even show correlate vasodilator responsiveness survival . Dynamic , real time change echocardiographic parameter previously evaluate predictor vasodilator responsiveness clinical outcome . The investigator examine whether echocardiographic change response inhale iloprost predict invasively derive vasodilator responsiveness help assess prognosis patient pulmonary hypertension , possibly even obviate need invasive testing .</detailed_description>
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Hypertension , Pulmonary</mesh_term>
	<mesh_term>Iloprost</mesh_term>
	<mesh_term>Nitric Oxide</mesh_term>
	<mesh_term>Vasodilator Agents</mesh_term>
	<criteria>Adult patient young 18 year age Recently diagnose pulmonary hypertension ( define RV systolic pressure ≥ 40 mmHg measure echocardiography ) , go invasive hemodynamic assessment pulmonary hypertension Normal leave ventricular function define leave ventricular ejection fraction ( LVEF ) great equal 50 % Heart failure ( LVEF &lt; 50 % , diastolic dysfunction &gt; stage 1 , history symptom leave heart failure ) Group II pulmonary hypertension 2+ high MR AI Inadequate echocardiographic window Pregnancy Systolic blood pressure ≤ 90 mmHg</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>pulmonary hypertension</keyword>
	<keyword>vasodilator challenge</keyword>
	<keyword>echocardiography</keyword>
	<keyword>outcome</keyword>
	<keyword>iloprost</keyword>
	<keyword>inhale nitric oxide</keyword>
</DOC>